 |
|
Clinical Response and Risk for Reported Suicidal Ideation and Suicide Attempts in Pediatric Antidepressant TreatmentA Meta-analysis of Randomized Controlled Trials
Jeffrey A. Bridge, PhD;
Satish Iyengar, PhD;
Cheryl B. Salary, MD;
Rémy P. Barbe, MD;
Boris Birmaher, MD;
Harold Alan Pincus, MD;
Lulu Ren, PhD;
David A. Brent, MD
JAMA. 2007;297:1683-1696.
Context The US Food and Drug Administration (FDA) has issued warnings that use of antidepressant medications poses a small but significantly increased risk of suicidal ideation/suicide attempt for children and adolescents.
Objective To assess the efficacy and risk of reported suicidal ideation/suicide attempt of antidepressants for treatment of pediatric major depressive disorder (MDD), obsessive-compulsive disorder (OCD), and non-OCD anxiety disorders.
Data Sources and Study Selection PubMed (1988 to July 2006), relevant US and British regulatory agency reports, published abstracts of important scientific meetings (1998-2006), clinical trial registries, and information from authors. Studies were published and unpublished randomized, placebo-controlled, parallel-group trials of second-generation antidepressants (selective serotonin reuptake inhibitors, nefazodone, venlafaxine, and mirtazapine) in participants younger than 19 years with MDD, OCD, or non-OCD anxiety disorders.
Data Extraction Information was extracted on study characteristics, efficacy outcomes, and spontaneously reported suicidal ideation/suicide attempt.
Data Synthesis Twenty-seven trials of pediatric MDD (n = 15), OCD (n = 6), and non-OCD anxiety disorders (n = 6) were selected, and risk differences for response and for suicidal ideation/suicide attempt estimated by random-effects methods. Pooled risk differences in rates of primary study-defined measures of responder status significantly favored antidepressants for MDD (11.0%; [95% confidence interval {CI}, 7.1% to 14.9%]), OCD (19.8% [95% CI, 13.0% to 26.6%), and non-OCD anxiety disorders (37.1% [22.5% to 51.7%]), corresponding to a number needed to treat (NNT) of 10 (95% CI, 7 to 15), 6 (4 to 8), and 3 (2 to 5), respectively. While there was increased risk difference of suicidal ideation/suicide attempt across all trials and indications for drug vs placebo (0.7%; 95% CI, 0.1% to 1.3%) (number needed to harm, 143 [95% CI, 77 to 1000]), the pooled risk differences within each indication were not statistically significant: 0.9% (95% CI, –0.1% to 1.9%) for MDD, 0.5% (–1.2% to 2.2%) for OCD, and 0.7% (–0.4% to 1.8%) for non-OCD anxiety disorders. There were no completed suicides. Age-stratified analyses showed that for children younger than 12 years with MDD, only fluoxetine showed benefit over placebo. In MDD trials, efficacy was moderated by age, duration of depression, and number of sites in the treatment trial.
Conclusions Relative to placebo, antidepressants are efficacious for pediatric MDD, OCD, and non-OCD anxiety disorders, although the effects are strongest in non-OCD anxiety disorders, intermediate in OCD, and more modest in MDD. Benefits of antidepressants appear to be much greater than risks from suicidal ideation/suicide attempt across indications, although comparison of benefit to risk varies as a function of indication, age, chronicity, and study conditions.
Author Affiliations: Department of Pediatrics and Columbus Children's Research Institute, The Ohio State University, Columbus (Dr Bridge); Department of Psychiatry and Western Psychiatric Institute & Clinic (Drs Iyengar, Salary, Barbe, Birmaher, and Brent) and Department of Statistics (Drs Iyengar and Ren), University of Pittsburgh, Pittsburgh, Pa; Department of Psychiatry, University Hospital of Geneva, Geneva, Switzerland (Dr Barbe); Department of Psychiatry, Columbia University College of Physicians and Surgeons, New York-Presbyterian Hospital, New York, NY (Dr Pincus); and the RAND Corporation, Santa Monica, Calif (Dr Pincus). Dr Ren is now with Amgen Inc, San Francisco, Calif.
RELATED LETTERS
Benefits and Harms of Pediatric Antidepressant Medications
Bruce Waslick
JAMA. 2007;298(6):626.
EXTRACT
| FULL TEXT
Benefits and Harms of Pediatric Antidepressant Medications
Jonathan L. Edwards, Karen K. Kirk, and Chand K. Midha
JAMA. 2007;298(6):626-627.
EXTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Health advisories: when good intentions go bad
Mamdani
CMAJ 2008;178:1025-1026.
FULL TEXT
Continuation Treatment With Antidepressants in Child and Adolescent Major Depression
Ryan
Am. J. Psychiatry 2008;165:411-412.
FULL TEXT
Fluoxetine Versus Placebo in Preventing Relapse of Major Depression in Children and Adolescents
Emslie et al.
Am. J. Psychiatry 2008;165:459-467.
ABSTRACT
| FULL TEXT
Depression: Focus on the Adolescent Male
Breland and Park
American Journal of Men's Health 2008;2:87-93.
A Depressed Adolescent at High Risk of Suicidal Behavior
Vitiello and Pearson
Am. J. Psychiatry 2008;165:323-328.
FULL TEXT
Switching to Another SSRI or to Venlafaxine With or Without Cognitive Behavioral Therapy for Adolescents With SSRI-Resistant Depression: The TORDIA Randomized Controlled Trial
Brent et al.
JAMA 2008;299:901-913.
ABSTRACT
| FULL TEXT
Uncritical positive regard? Issues in the efficacy and safety of psychotherapy
Nutt and Sharpe
J Psychopharmacol 2008;22:3-6.
Effects of Food and Drug Administration Warnings on Antidepressant Use in a National Sample
Olfson et al.
Arch Gen Psychiatry 2008;65:94-101.
ABSTRACT
| FULL TEXT
Pharmacotherapy and child psychiatry: is there a way forward?: INVITED COMMENTARY ON... CHILD PSYCHIATRY AND ITS RELATIONSHIP WITH THE PHARMACEUTICAL INDUSTRY
James
Adv. Psychiatr. Treat. 2008;14:10-16.
ABSTRACT
| FULL TEXT
Evidence-based treatment of adolescent major depression
Dubicka and Wilkinson
Evid. Based Ment. Health 2007;10:100-102.
FULL TEXT
NICE guidelines on depression in children and young people: not always following the evidence
Hodes and Garralda
Psychiatr. Bull. 2007;31:361-362.
FULL TEXT
Second generation antidepressants should remain an option for children and adolescents with depression or anxiety
BMJ 2007;335:607-607.
ABSTRACT
| FULL TEXT
A Developmental Perspective on the Controversy Surrounding the Use of SSRIs to Treat Pediatric Depression
Leckman and King
Am. J. Psychiatry 2007;164:1304-1306.
FULL TEXT
Early Evidence on the Effects of Regulators' Suicidality Warnings on SSRI Prescriptions and Suicide in Children and Adolescents
Gibbons et al.
Am. J. Psychiatry 2007;164:1356-1363.
ABSTRACT
| FULL TEXT
Suicide and Suicide Attempts in Adolescents
Shain and and the Committee on Adolescence
Pediatrics 2007;120:669-676.
ABSTRACT
| FULL TEXT
Benefits and Harms of Pediatric Antidepressant Medications
Waslick
JAMA 2007;298:626-626.
FULL TEXT
Benefits and Harms of Pediatric Antidepressant Medications
Edwards et al.
JAMA 2007;298:626-627.
FULL TEXT
JournalWatch
Arch. Dis. Child. 2007;92:730-731.
FULL TEXT
Suicide: scientific overview and relevance for trauma care providers
Crandall
Trauma 2007;9:213-220.
ABSTRACT
More on Antidepressants in Children and Adolescents: Analysis of Benefits and Risks
JWatch Pediatrics 2007;2007:1-1.
FULL TEXT
Benefits of Antidepressants Appear to Outweigh Risks in Children and Adolescents
JWatch General 2007;2007:1-1.
FULL TEXT
Antidepressants in Pediatric Patients: Benefits Might Outweigh Risks
JWatch Psychiatry 2007;2007:1-1.
FULL TEXT
|
